# Antihypertensive Response to Losartan and Genetic Polymorphisms

> **NCT00617877** · NA · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 800 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** losartan potassium
- **DRUG:** Comparator: Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00617877
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2009-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617877, "Antihypertensive Response to Losartan and Genetic Polymorphisms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00617877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*